PlumX Metrics
Embed PlumX Metrics

Temozolomide and pituitary tumors: Current understanding, unresolved issues, and future directions

Frontiers in Endocrinology, ISSN: 1664-2392, Vol: 9, Issue: JUN, Page: 318
2018
  • 48
    Citations
  • 0
    Usage
  • 53
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know